Associated Papers
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.
Sahin IH et al.
Npj Precision Oncology, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Guida M et al.
Journal of Translational Medicine, 2025
Leveraging oncology clinical case report data through the Cancer Knowledgebase (CKB).
Gokhale RH et al.
Personalized Medicine, 2025
Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.
Zhao X et al.
Translational Lung Cancer Research, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.
Menzer C et al.
European Journal of Cancer (oxford, England : 1990), 2025
Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal Cancer.
Xie L et al.
Molecules (basel, Switzerland), 2025
[A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib].
Wang Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2025
Dr. Kinase: predicting the drug-resistance hotspots of protein kinases.
Lin S et al.
Nucleic Acids Research, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Shared neoantigens' atlas for off-the-shelf cancer vaccine development.
Mauriello A et al.
Journal of Translational Medicine, 2025
RAS Pathway Mutations and Therapeutics in Vascular Anomalies.
Alharbi S et al.
Pediatric Blood & Cancer, 2025
Actionable Mutations and Survival Rates in Non-Small Cell Lung Cancer.
Al-Qaisi TS et al.
World Journal of Oncology, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice.
Parisi C et al.
Cancer, 2025
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.
Condoiu C et al.
Biomedicines, 2025
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.
Faulkner LG et al.
Cancer Investigation, 2025
Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing.
Matsushita K et al.
Scientific Reports, 2025
Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.
Afsar S et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2025
VE1 immunohistochemistry as a screening tool for BRAFV600E mutation in lung adenocarcinoma: evidence from a Montenegro National Cohort.
Campar B et al.
Folia Histochemica Et Cytobiologica, 2025
Braf-Mutant Melanomas: Biology and Therapy.
Pelosi E et al.
Current Oncology (toronto, Ont.), 2024
Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan.
Hida T et al.
Cancer Medicine, 2024
Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review.
Chmielewska I et al.
Translational Lung Cancer Research, 2024
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal location.
Küçükosmanoglu A et al.
Molecular Oncology, 2024
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.
Sementsov M et al.
Embo Molecular Medicine, 2024
Pathways and targeting avenues of BRAF in non-small cell lung cancer.
Imyanitov EN et al.
Expert Opinion on Therapeutic Targets, 2024
Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors.
Yi JR et al.
Journal of Stomatology, Oral and Maxillofacial Surgery, 2024
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
Haugh A et al.
American Journal of Clinical Dermatology, 2024
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape.
Planchard D et al.
Npj Precision Oncology, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors.
Roa P et al.
Cancers, 2024
Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.
Dobre EG et al.
International Journal of Molecular Sciences, 2024
Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways.
Wang X et al.
American Journal of Human Genetics, 2024
BRAFV600E Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.
Cheraghi S et al.
Medical Journal of the Islamic Republic of Iran, 2024
Deciphering the Functional Roles of Individual Cancer Alleles Across Comprehensive Cancer Genomic Studies.
Ma JY et al.
Biorxiv : the Preprint Server for Biology, 2023
Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas.
Kokkali S et al.
Cells, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.
Castellani G et al.
Cancers, 2023
Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility.
Talwar JV et al.
American Journal of Human Genetics, 2023
Multi-organ landscape of therapy-resistant melanoma.
Liu S et al.
Nature Medicine, 2023
Cutaneous Melanoma and Glioblastoma Multiforme Association-Case Presentation and Literature Review.
Orzan OA et al.
Diagnostics (basel, Switzerland), 2023